Immunovia publ AB (IMMNOV) - Total Liabilities

Latest as of December 2025: Skr23.48 Million SEK ≈ $2.53 Million USD

Based on the latest financial reports, Immunovia publ AB (IMMNOV) has total liabilities worth Skr23.48 Million SEK (≈ $2.53 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Immunovia publ AB operating cash flow efficiency to assess how effectively this company generates cash.

Immunovia publ AB - Total Liabilities Trend (2012–2025)

This chart illustrates how Immunovia publ AB's total liabilities have evolved over time, based on quarterly financial data. Check Immunovia publ AB (IMMNOV) asset resilience to evaluate the company's liquid asset resilience ratio.

Immunovia publ AB Competitors by Total Liabilities

The table below lists competitors of Immunovia publ AB ranked by their total liabilities.

Company Country Total Liabilities
Inbest Prime VII Inmuebles SOCIMI S.A.
MC:YINB7
Spain €9.93K
Relpol SA
WAR:RLP
Poland zł34.68 Million
Giga Media Ltd
NASDAQ:GIGM
USA $2.08 Million
Fitters Diversified Bhd
KLSE:9318
Malaysia RM79.06 Million
Samil Co.Ltd
KQ:032280
Korea ₩41.68 Billion
Way 2 Vat Ltd
AU:W2V
Australia AU$7.17 Million
Genmin Ltd
AU:GEN
Australia AU$33.20 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Immunovia publ AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Immunovia publ AB (IMMNOV) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.42 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.36 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Immunovia publ AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Immunovia publ AB (2012–2025)

The table below shows the annual total liabilities of Immunovia publ AB from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 Skr23.48 Million
≈ $2.53 Million
+9.74%
2024-12-31 Skr21.39 Million
≈ $2.30 Million
-32.49%
2023-12-31 Skr31.69 Million
≈ $3.41 Million
-44.19%
2022-12-31 Skr56.79 Million
≈ $6.11 Million
-5.21%
2021-12-31 Skr59.91 Million
≈ $6.45 Million
-3.03%
2020-12-31 Skr61.77 Million
≈ $6.65 Million
+0.02%
2019-12-31 Skr61.76 Million
≈ $6.65 Million
+300.25%
2018-12-31 Skr15.43 Million
≈ $1.66 Million
+10.42%
2017-12-31 Skr13.97 Million
≈ $1.50 Million
+106.15%
2016-12-31 Skr6.78 Million
≈ $729.47K
-12.06%
2015-12-31 Skr7.71 Million
≈ $829.53K
+146.21%
2014-12-31 Skr3.13 Million
≈ $336.92K
+23.92%
2013-12-31 Skr2.53 Million
≈ $271.87K
+51.13%
2012-12-31 Skr1.67 Million
≈ $179.89K
--

About Immunovia publ AB

ST:IMMNOV Sweden Diagnostics & Research
Market Cap
$14.70 Million
Skr136.55 Million SEK
Market Cap Rank
#25905 Global
#543 in Sweden
Share Price
Skr0.20
Change (1 day)
-5.58%
52-Week Range
Skr0.16 - Skr0.96
All Time High
Skr290.00
About

Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.